Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cabaletta Bio鈥檚 latest 10-K can read like an immunology textbook鈥攄ense tables on CARTA and CAART trial cohorts, layered milestone clauses, and pages of manufacturing risk factors. If you have ever searched 鈥淐abaletta Bio SEC filings explained simply鈥� or hunted for dosing data buried deep within, you know the challenge. Stock Titan turns those hundreds of pages into concise intelligence you can act on.
Our AI-powered summaries extract essentials from every Cabaletta Bio quarterly earnings report 10-Q filing, flagging R&D cash burn and RESET trial updates. AG真人官方-time alerts capture Cabaletta Bio insider trading Form 4 transactions the moment they hit EDGAR, so you never miss a Cabaletta Bio Form 4 insider transactions real-time disclosure. Need a Cabaletta Bio annual report 10-K simplified, a quick Cabaletta Bio earnings report filing analysis, or clarity on a sudden Cabaletta Bio 8-K material events explained? Ask the platform鈥攗nderstanding Cabaletta Bio SEC documents with AI becomes effortless.
- Pipeline progress 鈥� track clinical milestones straight from 8-K trial announcements.
- Capital strategy 鈥� examine collaboration revenue, at-the-market offerings, and cash runway inside each 10-Q.
- Insider sentiment 鈥� monitor Cabaletta Bio executive stock transactions Form 4 and Cabaletta Bio proxy statement executive compensation for context.
Every filing type鈥�10-K, 10-Q, 8-K, S-1, and more鈥攊s updated in seconds, complete with expert commentary. Spend minutes, not weekends, staying ahead of Cabaletta Bio disclosures.
Cabaletta Bio鈥檚 Q2-25 10-Q shows an enlarged pipeline but a materially higher cash burn. Operating expenses jumped 52% YoY to $45.9 M, driven by a 61% rise in R&D as the company advanced its CD19 CARTA program rese-cel across five autoimmune indications. The quarterly net loss widened to $45.1 M (-$0.73/sh) from $27.6 M (-$0.56/sh) one year ago; six-month loss reached $81.1 M.
Liquidity improved through an equity/warrant raise but a going-concern warning remains. In June the company issued 39.2 M shares plus 10.8 M pre-funded warrants, netting $93.6 M; an additional $2.6 M was raised via ATM sales. Cash & cash equivalents fell to $145.6 M but were supplemented by $49.1 M of new U.S. Treasury investments, lifting total cash & investments to $194.7 M. Lease-related assets boosted total assets to $224.5 M while finance lease liabilities rose to $20.3 M. Despite the capital infusion, management states that current resources 鈥渕ay not be sufficient鈥� for 12 months, citing substantial doubt about going concern; cash burn from operations was $61.2 M in 1H-25.
Prudential Financial, Inc. (PFI) has filed Amendment No. 2 to Schedule 13G for Cabaletta Bio, Inc. (NASDAQ: CABA). As of 30 June 2025, PFI reports beneficial ownership of 10,391,167 common shares, representing 7.4 % of CABA鈥檚 outstanding stock. All shares are held with shared voting and dispositive power; PFI claims no sole authority over the shares.
The position is held through two investment-management subsidiaries: Jennison Associates LLC (10,107,167 shares; 7.2 %) and PGIM, Inc. (284,000 shares; 0.2 %). PFI classifies itself as a 鈥減arent holding company/ control person鈥� under Rule 13d-1(b)(1)(ii)(G) and certifies the shares are held in the ordinary course of business, not to influence control of Cabaletta Bio.
Key takeaways for investors: 1) PFI remains a >5 % holder, indicating continued institutional support; 2) the stake size affords PFI meaningful, though not controlling, influence in shareholder matters; 3) no sale intention or activist purpose is disclosed.
Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company鈥檚 92.94 million shares outstanding.
Citadel Advisors鈥搈anaged funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.
FAQ
What is the current stock price of Cabaletta Bio (CABA)?
What is the market cap of Cabaletta Bio (CABA)?
